Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses

Psychopharmacology

Volumn 232, Issue 18, 2015, Pages 3443-3453

  Sahlholm, Kristoffer ^a,c   Sijbesma, Jurgen W A ^a   Maas, Bram ^a   Kwizera, Chantal ^a   Marcellino, Daniel ^b   Ramakrishnan, Nisha K ^a   Dierckx, Rudi A J O ^a   Elsinga, Philip H ^a   Van Waarde, Aren ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

^{11< sup>C raclopride; 11< sup>C SA4503; Kinetic analysis; MicroPET; Receptor occupancy}

Indexed keywords

CUTAMESINE C 11; DOPAMINE 2 RECEPTOR; PRIDOPIDINE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG; CARBON; CUTAMESINE; DOPAMINE RECEPTOR BLOCKING AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; RACLOPRIDE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG UPTAKE; ISOTOPE LABELING; MALE; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RECEPTOR OCCUPANCY; ANIMAL; METABOLISM; NEOSTRIATUM;

ANIMALS; CARBON RADIOISOTOPES; DOPAMINE ANTAGONISTS; MALE; NEOSTRIATUM; PIPERAZINES; PIPERIDINES; RACLOPRIDE; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, SIGMA;

EID: 84939247927     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-3997-8     Document Type: Article

References (41)

1. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN (2010) Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30:46-50
2. de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J, MermaiHD study investigators (2011) Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 10:1049-1057
3. DiPardo A, Maglione V, Favellato MG, Amico E, Squitieri F (2013) Potential neuroprotective effects of pridopidine in Huntington's disease [abstract]. Mov Disord 28(Suppl 1):768
4. Dyhring T, Nielsen EØ, Sonesson C, Pettersson F, Karlsson J, Svensson P, Christophersen P, Waters N (2010) The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 628:19-26
5. Ekesbo A, Torstenson R, Hartvig P, Carlsson A, Sonesson C, Waters N, Tedroff J, Långström B (1999) Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains. Neuropharmacology 38:331-338
6. Farde L, Pauli S, Hall H, Eriksson L, Halldin C, Högberg T, Nilsson L, Sjögren I, Stone-Elander S (1988) Stereoselective binding of 11C-raclopride in living human brain-a search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology 94:471-478
7. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE (2009) The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323:934-937
8. Francardo V, Bez F, Wieloch T, Nissbrandt H, Ruscher K, Cenci MA (2014) Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain 137:1998-2014
9. Guitart X, Codony X, Monroy X (2004) Sigma receptors: biology and therapeutic potential. Psychopharmacology 174:301-319
10. Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP (2011) Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 15:557-577
11. Ishiwata K, Kobayashi T, Kawamura K, Matsuno K (2003) Age-related changes of the binding of [3H]SA4503 to sigma1 receptors in the rat brain. Ann Nucl Med 17:73-77
12. Kara E, Lin H, Svensson K, Johansson AM, Strange PG (2010) Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol 161:1343-1350
13. Kawamura K, Elsinga PH, Kobayashi T, Ishii S, Wang WF, Matsuno K, Vaalburg W, Ishiwata K (2003) Synthesis and evaluation of 11C-and 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol 30:273-284
14. Kieburtz K, McGarry A, McDermott M, Kayson E, Harrison M, Marder K, Walker F, Corey-Bloom J, Goldstein J, Hyson C, Megans J, Huntington Study Group HART Investigators (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord 28:1407-1415
15. Köhler C, Hall H, Ogren SO, Gawell L (1985) Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251-2259
16. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
17. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451
18. Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK, Osman S, Bloomfield PM, Jones T, Patsalos PN (1995) Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 15:152-165
19. Matsumoto RR, Shaikh J, Wilson LL, Vedam S, Coop A (2008) Attenuation of methamphetamine-induced effects through the antagonism of sigma receptors: evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol 18:871-881
20. Maurice T, Su TP (2009) The pharmacology of sigma-1 receptors. Pharmacol Ther 124:195-206
21. McCormick PN, Ginovart N, Wilson AA (2011) Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release. Mol Imaging Biol 13:737-746
22. Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, Kapur S (2006) The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318:810-818
23. Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, Mallol J, Cortés A, Casadó V, Canela EI, Ortiz J, Fuxe K, Lluís C, Ferré S, Franco R (2010) Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci USA 107:18676-18681
24. Navarro G, Moreno E, Bonaventura J, Brugarolas M, Farré D, Aguinaga D, Mallol J, Cortés A, Casadó V, Lluís C, Ferre S, Franco R, Canela E, McCormick PJ (2013) Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS One 8, e61245
25. Nilsson MK, Carlsson ML (2013) The monoaminergic stabilizer (-)-OSU6162 reverses delay-dependent natural forgetting and improves memory impairment induced by scopolamine in mice. Neuropharmacology 75:399-406
26. Pettersson F, Ponten H, Waters N, Waters S, Sonesson C (2010) Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (Huntexil, Pridopidine, ACR16). J Med Chem 53:2510-2520
27. Ponten H, Kullingsjö J, Lagerkvist S, Martin P, Pettersson F, Sonesson C, Waters S, Waters N (2010) In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 644:88-95
28. Ponten H, Kullingsjö J, Sonesson C, Waters S, Waters N, Tedroff J (2013) The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model. Eur J Pharmacol 698:278-285
29. Ramakrishnan NK, Visser AK, Schepers M, Luurtsema G, Nyakas CJ, Elsinga PH, Ishiwata K, Dierckx RA, van Waarde A (2014) Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with 11C-SA4503 and microPET. Psychopharmacology 231:3997-4006
30. Ruiz C, Casarejos MJ, Rubio I, Gines S, Puigdellivol M, Alberch J, Mena MA, de Yebenes JG (2012) The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins. Brain Res 1459:100-112
31. Rung JP, Carlsson A, Markinhuhta KR, Carlsson ML (2005) The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry 29:833-839
32. Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A, Carlsson ML (2008) Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm 115:899-908
33. Sahlholm K, Århem P, Fuxe K, Marcellino D (2013) The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the σ-1 receptor. Mol Psychiatry 18:12-14
34. Sahlholm K, Marcellino D, Nilsson J, Ögren SO, Fuxe K, Århem P (2014) Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor. Int J Neuropsychopharmacol 17:149-155
35. Seeman P, Tokita K, Matsumoto M, Matsuo A, Sasamata M, Miyata K (2009) The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors. Synapse 63:930-934
36. Svensson KA, Falcone JF, Johansson AM, Perry KW, Fell MJ (2009) The actions of the dopamine stabilizer ACR16, but not (-)-OSU6162, in behavioral and neurochemical assays are not dependent on the presence of functional dopamine D2 receptors. In: 39th Annual Meeting, Society for Neuroscience, Chicago, October 2009
37. Tolboom N, Berendse HW, Leysen JE, Yaqub M, van Berckel BN, Schuit RC, Ponsen MM, Bakker E, Hoetjes NJ, Windhorst AD, Carlsson ML, Lammertsma AA, Carlsson A (2015) The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [11C]raclopride PET study in healthy human subjects. Neuropsychopharmacology 40:472-479
38. van Waarde A, Ramakrishnan NK, Rybczynska AA, Elsinga PH, Ishiwata K, Nijholt IM, Luiten PG, Dierckx RA (2011) The cholinergic system, sigma-1 receptors and cognition. Behav Brain Res 221:543-554
39. Visser AK, De Vries EF, Ramakrishnan NK, Willemsen AT, Bosker FJ, den Boer JA, Dierckx RA, van Waarde A (2013) Analysis of 5-HT2A receptor binding with [11C]MDL 100907 in rats: optimization of kinetic modeling. Mol Imaging Biol 15:730-738
40. Waters S, Ponten H, Eding M, Svanberg B, Keamer D, Waters N (2014) The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression. J Neural Transm 121:1337-1347
41. Westphalen RI, Desai KM, Hemmings HC (2013) Presynaptic inhibition of the release of multiple major central nervous system neurotransmitter types by the inhaled anaesthetic isoflurane. Br J Anaesth 110:592-599